New and updated preclinical and clinical data presented by biopharma firms at the American Association for Cancer Research virtual International Conference on Molecular Targets and Cancer Therapeutics, including: Aileron, Amgen, Amunix, Bridgebio, Clovis, Cogent, Curis, Deciphera, Essa, Forma, Gennao, Hummingbird, Ikena, Immunome, IMV, Kineta, Kinnate, Medicenna, Monte Rosa, Nuvalent, Oric, Phio, Prelude, Relay, Salarius, Second Genome, Spectrum, Turning Point.
Data from two phase I studies from Prelude Therapeutics Inc. helped open the American Association for Cancer Research virtual International Conference on Molecular Targets and Cancer Therapeutics on Oct. 7 but tugged the company’s stock sharply downward.
The start of a phase Ib/II trial with nanatinostat by Viracta Therapeutics Inc. has brought new attention to the burgeoning field of synthetic lethality, where a number of players are piquing the interest of Wall Street.
DUBLIN – Iomx Therapeutics AG raised €65 million (US$75.4 million) in a series B round, which will enable it to move its lead immuno-oncology program into the clinic. The funding will also allow it to take a second program into IND-enabling studies and to back-fill its pipeline with additional programs.
Exo Therapeutics Inc. has completed an oversubscribed series B financing for $78 million allowing the small-molecule company to continue developing therapies for treating cancer and inflammation.
Exo’s pipeline, created from its Exosight platform, has preclinical candidates that bind exosites, which are distal binding pockets for reprogramming enzyme activity. The exosite drugs include structural and computational biology, protein engineering and DNA-encoded libraries.
Xencor Inc. and Janssen Biotech Inc., already partners on the development of bispecific antibodies against CD28 for prostate cancer, have reached a second agreement licensing to Janssen exclusive development and commercialization rights to Xencor's phase I bispecific antibody, plamotamab, for the treatment of B-cell malignancies, both as a monotherapy and in combination regimens.
Low-grade gliomas with mutated isocitrate dehydrogenase-1 (IDH1) produced and secreted higher levels of the cytokine granulocyte colony-stimulating factor (G-CSF) than other glioma types, which improved their antitumor immune response in animal models.
Cell therapy developer Cellular Biomedicine Group Inc. (CBMG) completed a $120 million series A financing, its first since becoming a private company. The funds will benefit the U.S. and China-based firm’s CAR T pipeline, and the round was jointly led by Astrazeneca-CICC Fund, Sequoia Capital China and Yunfeng Capital. Existing investors including GIC Private Ltd. (formerly Government of Singapore Investment Corp.) and TF Capital also took part.
Astellas Pharma Inc. and Seagen Inc. received approval through a priority review from Japan's Ministry of Health, Labour and Welfare for Padcev (enfortumab vedotin) to treat radically unresectable urothelial carcinoma that has progressed after chemotherapy. The green light for the antibody-drug conjugate is based on the global phase III EV-301 clinical trial, which included sites in Japan.
LONDON – The scientific pioneer behind T-cell receptors has taken the helm of a new biotech he believes has the technology to overcome current shortcomings of cancer immunotherapy. Bent Jakobsen, co-founder and long-term chief scientific officer of Immunocore plc and of CAR T-cell specialist Adaptimmune plc, is now CEO of Accession Therapeutics Ltd., set up to develop what is claimed as the first oncolytic virus to be genetically engineered to exclusively infect cancer cells.
RSS
